An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

Trial Profile

An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Namacimab (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions; First in man
  • Sponsors Bird Rock Bio
  • Most Recent Events

    • 13 Sep 2018 According to a Bird Rock Bio media release, the company announced today the it has successfully completed its final patient visit in this study.
    • 13 Sep 2018 According to a Bird Rock Bio media release, study results from the clinical trial are anticipated prior to the American Society of Nephrology's "Kidney Week" in October and AASLD's The Liver Meeting 2018 in November 2018.
    • 13 Sep 2018 Status changed from active, no longer recruiting to completed, according to a Bird Rock Bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top